← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Nanometics, Llc
La Jolla, CA
$13,911,499
Total funding
15
Grants
Funding over time
peak $2.2M · FY2011–24$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,911,499 · 15
By mechanism
R44$11,594,803 · 6
R43$2,091,696 · 8
R41$225,000 · 1
Investigators at Nanometics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Organocatalysis for the treatment of sickle cell disease$1,367,340
R44 · FY2013 · HL
Organocatalysis for the treatment of sickle cell disease$1,228,297
R44 · FY2014 · HL
The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer$1,000,000
R44 · FY2021 · CA
The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer$1,000,000
R44 · FY2020 · CA
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis$1,000,000
R44 · FY2023 · CA
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis$1,000,000
R44 · FY2024 · CA
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome$999,914
R44 · FY2017 · CA
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome$999,333
R44 · FY2019 · CA
Schiff base forming sunscreen filters for long-wear UV protection$750,000
R44 · FY2015 · CA
Schiff base forming sunscreen filters for long-wear UV protection$749,999
R44 · FY2014 · CA
The Translational Development of a Therapeutic For Triple Negative Breast Cancer$749,960
R44 · FY2016 · CA
The Translational Development of a Therapeutic For Triple Negative Breast Cancer$749,959
R44 · FY2015 · CA
Furthering the clinical development of a first in class, water resistant sunscreen to meet emerging environmental regulations$398,768
R43 · FY2021 · CA
A novel small molecule Bax activator as an oral therapeutic for the treatment of lung cancer.$299,676
R43 · FY2019 · CA
Schiff base forming sunscreen filters for long-wear UV protection$250,540
R43 · FY2012 · CA
Organocatalysis for the Treatment of Sickle Cell Disease.$243,469
R43 · FY2011 · HL
Orally available transition state inhibitors for triple negative breast cancer$225,000
R41 · FY2014 · CA
A targeted drug for the treatment of inflammation in cystic fibrosis lung disease$224,958
R43 · FY2016 · HL
A targeted immunomodulator for the treatment of acute sickle crisis$224,901
R43 · FY2015 · TR
The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer$224,831
R43 · FY2018 · CA